Osaka University:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Osaka University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9292
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Osaka University (OU) is an educational university that provides undergraduate and graduate courses. The university provides courses in dentistry, economics, engineering, engineering science, foreign studies, human sciences, law and politics, medicine, information science and technology, language and culture, pharmaceutical sciences and biosciences, among others. It offers research areas such as microbial diseases, scientific and industrial research, protein research, social and economic, laser engineering, joining and welding research, and others. OU provides hospital services such as dental and university hospital services. The University has operations in the US, Thailand, China and the Netherlands, among others. OU is headquartered in Suita, Japan.

Osaka University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Osaka University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Osaka University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Osaka University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Osaka University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Osaka University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Osaka University, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Mitsubishi Tanabe Pharma and Osaka University Enter into Agreement 11
KAN Research Institute Enters into Development Agreement with Six Research Organizations 12
Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 14
Oncolys Biopharma Enters into Research Agreement with Osaka University 15
BIKEN Enters into Distribution Agreement with Chiba Prefectural Institute of Health 16
Chugai Pharmaceutical Enters into Agreement with Osaka University 17
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 18
Takeda Pharma Enters Into Research Agreement With Osaka University 19
Licensing Agreements 20
Japan Agency for Medical Research and Development Enters into Licensing Agreement with Osaka University 20
NobelPharma Enters into Licensing Agreement with Osaka University 21
BIKEN Enters into Licensing Agreement with Osaka University 22
FunPep Enters into Licensing Agreement with Osaka University 23
Osaka University – Key Competitors 24
Osaka University – Key Employees 25
Osaka University – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 28
Government and Public Interest 28
Aug 09, 2018: Anticancer drugs delivered by a new drug delivery system reduce tumor size 28
May 30, 2018: Telix Pharmaceuticals and Osaka University receive Japan Science and Technology Agency Funding for Alpha Nuclide Research 29
Apr 18, 2018: Researchers uncover origin of virus-fighting plasma B cells 30
Dec 20, 2017: CD4 T Cells, Xenobiotic Transporters, and Metabolites in Inflammatory Bowel Diseases 31
Nov 07, 2017: Osaka University: New Strategy for Multiple Myeloma Immunotherapy 32
Oct 26, 2017: Successful Cardiogenic Shock Treatment Using a Percutaneous Left Ventricular Assist Device 33
Sep 15, 2017: Novel Small Antibody Fragment: A Valuable Tool in Crystallography 34
Aug 22, 2017: The Pancreas provides a potential drug candidate for brain disease 35
Product News 36
Oct 29, 2018: Experimental vaccine may reduce post-stroke blood clot risk 36
Mar 26, 2018: New Breakthrough in Treatment for Rare Skin Condition 37
Other Significant Developments 38
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Osaka University, Pharmaceuticals & Healthcare, Key Facts 2
Osaka University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Osaka University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Osaka University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Osaka University, Deals By Therapy Area, 2012 to YTD 2018 8
Osaka University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Mitsubishi Tanabe Pharma and Osaka University Enter into Agreement 11
KAN Research Institute Enters into Development Agreement with Six Research Organizations 12
Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 14
Oncolys Biopharma Enters into Research Agreement with Osaka University 15
BIKEN Enters into Distribution Agreement with Chiba Prefectural Institute of Health 16
Chugai Pharmaceutical Enters into Agreement with Osaka University 17
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 18
Takeda Pharma Enters Into Research Agreement With Osaka University 19
Japan Agency for Medical Research and Development Enters into Licensing Agreement with Osaka University 20
NobelPharma Enters into Licensing Agreement with Osaka University 21
BIKEN Enters into Licensing Agreement with Osaka University 22
FunPep Enters into Licensing Agreement with Osaka University 23
Osaka University, Key Competitors 24
Osaka University, Key Employees 25
Osaka University, Other Locations 26
Osaka University, Subsidiaries 26

List of Figures
Osaka University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Osaka University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Osaka University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Osaka University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Osaka University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Osaka University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Osaka University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Osaka University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Osaka University:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TPI Composites Inc (TPIC):企業の財務・戦略的SWOT分析
    TPI Composites Inc (TPIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • F5 Networks, Inc. (FFIV):企業の財務・戦略的SWOT分析
    F5 Networks, Inc. (FFIV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Virginia Electric and Power Company:企業の発電所・SWOT分析2018
    Virginia Electric and Power Company - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Neuway Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Neuway Pharma GmbH (Neuway) is a provider of preclinical and clinical development for the treatment of central nervous system diseases. The company provides proprietary CNS drug delivery platform facilitates the transport of active drug substances through the blood-brain barrier. Its technol …
  • Banque de Luxembourg:企業の戦略・SWOT・財務情報
    Banque de Luxembourg - Strategy, SWOT and Corporate Finance Report Summary Banque de Luxembourg - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • ethris GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Ethris GmbH (Ethris) is a biotech company that develops RNA-based therapies. The company develops therapeutics based on its proprietary platform technologies. It uses technologies including magnetovax and SNIM RNA. Ethris’ magnetovax is a platform for personalized tumor vaccines localized an …
  • Robert Half International Inc (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Defense Commissary Agency:企業の戦略的SWOT分析
    Defense Commissary Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Guangzhou Improve Medical Instruments Co Ltd (300030):医療機器:M&Aディール及び事業提携情報
    Summary Guangzhou Improve Medical Instruments Co Ltd (Improve Medical) is a medical devices company that offers medical products, technologies, and services for clinical laboratory and clinical nursing. The company’s products include Improvacuter evacuated blood collection systems, Impromini capilla …
  • Cypress Semiconductor Corporation (CY):企業の財務・戦略的SWOT分析
    Cypress Semiconductor Corporation (CY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Firmenich SA:企業の戦略的SWOT分析
    Firmenich SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Detroit Medical Center:企業の戦略的SWOT分析
    Detroit Medical Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Thales Deutschland GmbH:企業の戦略・SWOT・財務情報
    Thales Deutschland GmbH - Strategy, SWOT and Corporate Finance Report Summary Thales Deutschland GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Olink Proteomics AB:医療機器:M&Aディール及び事業提携情報
    Summary Olink Proteomics AB (Olink) is a biotechnology company that offers products and services for human protein biomarker research. The company provides portfolio of products such as biomarkers, cardiovascular diseases panels, neurological disease panels, inflammation panels and oncology panels. …
  • HSS Engineers Berhad (HSSEB):企業の財務・戦略的SWOT分析
    HSS Engineers Berhad (HSSEB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • KT Corporation:企業の戦略・SWOT・財務情報
    KT Corporation - Strategy, SWOT and Corporate Finance Report Summary KT Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • ShanPar Industries Pvt. Ltd. :企業の戦略・SWOT・財務情報
    ShanPar Industries Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report Summary ShanPar Industries Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • ADDvise Group AB (ADDV A):企業の財務・戦略的SWOT分析
    Summary ADDvise Group AB (ADDvise), formerly ADDvise Lab Solutions AB, is a medical device company that manufactures and markets healthcare and laboratory equipment. The company offers laboratory products such as laboratory equipments, furnishings, safety ventilation, centrifuges, climate chambers, …
  • Toho Gas Co Ltd (9533):企業の財務・戦略的SWOT分析
    Toho Gas Co Ltd (9533) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Akbank TAS (AKBNK):企業の財務・戦略的SWOT分析
    Akbank TAS (AKBNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆